* |
If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) |
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,750 RSUs which fully vest on 8/3/2014; 1,245 RSUs which fully vest in 2 installments of 613 and 622 on 4/25/2014 and 4/25/2015, respectively; 1,500 RSUs which vest in 2 equal installments of 495 each on 4/27/2014 and 4/27/2015 and one installment of 510 on 4/27/2016; 840 RSUs which vest in 2 equal installments of 277 each on 4/26/2015 and 4/26/2016 and one installment of 286 on 4/26/2017; and 9,226 RSUs which vest in 2 equal installments of 4,163 each on 4/26/2015 and 4/26/2017. |
(2) |
These shares include 239 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount. |
(3) |
11,250 of these stock options are exercisable immediately and the remaining 3,750 are exercisable on 8/30/2014. |
(4) |
2,145 of these stock options are exercisable immediately and the remaining 4,355 are exercisable in two installments of 2,145 and 2,210 on 4/25/2014 and 4/25/2015, respectively. |